Pill Identifier App

Generic Lamisil Availability

Lamisil is a brand name of terbinafine, approved by the FDA in the following formulation(s):

LAMISIL (terbinafine hydrochloride - granule;oral)

  • Manufacturer: NOVARTIS
    Approval date: September 28, 2007
    Strength(s): EQ 125MG BASE/PACKET, EQ 187.5MG BASE/PACKET [RLD]

LAMISIL (terbinafine hydrochloride - tablet;oral)

  • Manufacturer: NOVARTIS
    Approval date: May 10, 1996
    Strength(s): EQ 250MG BASE [RLD] [AB]

Has a generic version of Lamisil been approved?

Yes. The following products are equivalent to Lamisil:

terbinafine hydrochloride tablet;oral

  • Manufacturer: APOTEX
    Approval date: July 2, 2007
    Strength(s): EQ 250MG BASE [AB]
  • Manufacturer: AUROBINDO PHARMA
    Approval date: July 2, 2007
    Strength(s): EQ 250MG BASE [AB]
  • Manufacturer: BRECKENRIDGE PHARM
    Approval date: June 4, 2010
    Strength(s): EQ 250MG BASE [AB]
  • Manufacturer: CIPLA LTD
    Approval date: July 2, 2007
    Strength(s): EQ 250MG BASE [AB]
  • Manufacturer: DR REDDYS LABS INC
    Approval date: July 2, 2007
    Strength(s): EQ 250MG BASE [AB]
  • Manufacturer: GLENMARK GENERICS
    Approval date: July 2, 2007
    Strength(s): EQ 250MG BASE [AB]
  • Manufacturer: HARRIS PHARM
    Approval date: July 2, 2007
    Strength(s): EQ 250MG BASE [AB]
  • Manufacturer: INVAGEN PHARMS
    Approval date: July 2, 2007
    Strength(s): EQ 250MG BASE [AB]
  • Manufacturer: MYLAN
    Approval date: July 2, 2007
    Strength(s): EQ 250MG BASE [AB]
  • Manufacturer: ORCHID HLTHCARE
    Approval date: July 2, 2007
    Strength(s): EQ 250MG BASE [AB]
  • Manufacturer: TEVA
    Approval date: July 2, 2007
    Strength(s): EQ 250MG BASE [AB]
  • Manufacturer: WOCKHARDT
    Approval date: July 2, 2007
    Strength(s): EQ 250MG BASE [AB]

Note: No generic formulation of the following product is available.

  • terbinafine hydrochloride - granule;oral

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lamisil. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Lamisil.

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
Hide
(web1)